ERCC5 and breast carcinoma: However, our meta-analysis suggests that there is no statistical evidence for an association between the ERCC5 Asp1104His polymorphism and overall cancer risk, which is consistent with the previous two meta-analyses conducted in breast cancer and melanoma, respectively.